Research output per year
Research output per year
Abstract
Objectives:
Chronic lymphocytic leukaemia (CLL) is associated with secondary immunodeficiency, but mechanistic insight into the dynamics of B cell responses is lacking. While altered non-malignant B cell composition is already present in the early stages of CLL, it is unknown how this impacts foreign antigen-specific B cell differentiation, such as SARS-CoV-2 vaccination in untreated and chemotherapy-treated patients.
Materials and Methods:
We recruited CLL patients who met the WHO-2017 and the International Workshop on CLL diagnostic criteria; CLL patients were either treatment naïve (CLL-TN) (n=23) or chemotherapy-receiving (CLL-CTx) (n=11). The healthy control group (HCs) (n=16) was composed of age- and sex-matched individuals. We characterized the overall non-malignant B cell landscape in relation to the development and phenotype of SARS-CoV-2 spike protein-specific B cells in CLL-TN and CLL-CTx patients compared to HCs following SARS-CoV-2 vaccination.
Using flow cytometry, we analysed the number and phenotype of B cells with reactivity against the SARS-CoV- 2 spike protein among peripheral blood mononuclear cells. Fluorochrome-labelled antibodies against CD24, CD38, CD27, CD11c, CXCR5, IgM, IgD and IgG allowed us to further assess B cell development, differentiation, and function. Anti-SARS-CoV-2 spike IgG levels were determined by ELISA. Results were considered statistically significant at p<0.05.
Results:
Despite prominent alterations in peripheral non-malignant B cell subsets in patients with CLL, the absolute numbers of circulating SARS-CoV-2 spike-specific B cells in CLL-TN and CLL-CTx were comparable to HCs. Furthermore, when characterizing the phenotype of SARS-CoV-2 spike-specific B cells, approximately half were IgG class-switched and only a minority had the IgD-CD27- double negative B cell phenotype in all groups. Preserved SARS-CoV-2 response was supported by anti-SARS-CoV-2 spike IgG levels.
Conclusions:
These data suggest that despite the major alterations in B cell subsets, the differentiation of SARS-CoV-2 spike-specific B cells is preserved in CLL-TN and CLL-CTx patients.
Chronic lymphocytic leukaemia (CLL) is associated with secondary immunodeficiency, but mechanistic insight into the dynamics of B cell responses is lacking. While altered non-malignant B cell composition is already present in the early stages of CLL, it is unknown how this impacts foreign antigen-specific B cell differentiation, such as SARS-CoV-2 vaccination in untreated and chemotherapy-treated patients.
Materials and Methods:
We recruited CLL patients who met the WHO-2017 and the International Workshop on CLL diagnostic criteria; CLL patients were either treatment naïve (CLL-TN) (n=23) or chemotherapy-receiving (CLL-CTx) (n=11). The healthy control group (HCs) (n=16) was composed of age- and sex-matched individuals. We characterized the overall non-malignant B cell landscape in relation to the development and phenotype of SARS-CoV-2 spike protein-specific B cells in CLL-TN and CLL-CTx patients compared to HCs following SARS-CoV-2 vaccination.
Using flow cytometry, we analysed the number and phenotype of B cells with reactivity against the SARS-CoV- 2 spike protein among peripheral blood mononuclear cells. Fluorochrome-labelled antibodies against CD24, CD38, CD27, CD11c, CXCR5, IgM, IgD and IgG allowed us to further assess B cell development, differentiation, and function. Anti-SARS-CoV-2 spike IgG levels were determined by ELISA. Results were considered statistically significant at p<0.05.
Results:
Despite prominent alterations in peripheral non-malignant B cell subsets in patients with CLL, the absolute numbers of circulating SARS-CoV-2 spike-specific B cells in CLL-TN and CLL-CTx were comparable to HCs. Furthermore, when characterizing the phenotype of SARS-CoV-2 spike-specific B cells, approximately half were IgG class-switched and only a minority had the IgD-CD27- double negative B cell phenotype in all groups. Preserved SARS-CoV-2 response was supported by anti-SARS-CoV-2 spike IgG levels.
Conclusions:
These data suggest that despite the major alterations in B cell subsets, the differentiation of SARS-CoV-2 spike-specific B cells is preserved in CLL-TN and CLL-CTx patients.
| Original language | English |
|---|---|
| Pages | 98 |
| Publication status | Published - 26 Mar 2025 |
| Event | RSU Research week 2025: Research week 2025 - 16 Dzirciema Street, Riga, Rīga, Latvia Duration: 24 Mar 2025 → 28 Mar 2025 https://rw2025.rsu.lv/ https://rw2025.rsu.lv/knowledge-use-practice https://rw2025.rsu.lv/places https://rw2025.rsu.lv/society-health-welfare |
Conference
| Conference | RSU Research week 2025 |
|---|---|
| Abbreviated title | RW2025 |
| Country/Territory | Latvia |
| City | Rīga |
| Period | 24/03/25 → 28/03/25 |
| Other | International Conference on Medical and Health Research. RSU Scientific Conference |
| Internet address |
Field of Science*
- 3.2 Clinical medicine
Publication Type*
- 3.4. Other publications in conference proceedings (including local)
Access to Document
Fingerprint
Dive into the research topics of 'Antigen-specific B cell Responses in Treatment Naive and Chemotherapy-Receiving Chronic Lymphocytic Leukemia Patients'. Together they form a unique fingerprint.Research output
- 1 Book
-
Rīga Stradiņš University International Research Conference on Medical and Health Care Sciences “Knowledge for Use in Practice”: Abstracts, 26-28 March, 2025
Rīga Stradiņš University, 2025, Rīga: Rīga Stradiņš University. 478 p.Research output: Book/Report › Book
Open Access